Orasis Pharmaceuticals launches Qlosi for presbyopia treatment in the U.S.

Orasis Pharmaceuticals has announced the U.S. availability of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel prescription eye drop designed to treat presbyopia, or age-related blurry near vision, according to a company press release.

Qlosi features the company’s proprietary EyeQ Formulation, which optimizes efficacy while minimizing side effects. The formulation includes the lowest approved concentration of pilocarpine at a near-neutral pH for better bioavailability, is preservative-free in single-use vials, and contains lubricants for added comfort.

Patients can use Qlosi flexibly, applying one drop per eye for specific tasks or up to 2 drops daily for an extended effect lasting up to 8 hours.

Qlosi enhances near vision by adjusting pupil size to create a pinhole effect, which extends depth of field and improves focus on close objects without significantly affecting distance vision. Its FDA approval was supported by Phase 3 NEAR-1 and NEAR-2 clinical trials, which successfully met primary and key secondary goals by Day 8.

“We are proud to deliver Qlosi, a solution that ushers in a new era in near vision correction and aims to empower patients, providing Qlosi Clear Moments through improved near vision,” said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals. “Our goal has always been to improve near vision for the millions of people struggling with presbyopia, give them a break from readers, and provide eye care professionals with an additional option to optimize care for their patients.”